Generic Name: bosutinib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Bosulif is a kinase inhibitor approved for adults with newly diagnosed or previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.
Bosulif targets BCR-ABL, an abnormal tyrosine kinase produced by the Philadelphia chromosome mutation in people with chronic myeloid leukemia (CML). It also inhibits tyrosine kinases in the SRC family.
Studies showed that Bosulif prevents proliferation of blood cells that grow out of control in people with Ph+ chronic myeloid leukemia. In the BFORE trial, 47 percent of patients with newly diagnosed CML had a major molecular response at 12 months. It was approved for CML on December 19, 2018.
Bosulif is a tablet taken once daily with food.
Common side effects include diarrhea, nausea, abdominal pain and skin rash. Bosulif can cause depletion of white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potentially serious side effects may include severe swelling or edema and gastrointestinal, liver and kidney problems. Bosulif may cause fetal harm if used during pregnancy.
For More Info: https://www.bosulif.com/
Patient Assistance Program Info: https://www.pfizeroncologytogether.com/
Last Reviewed: November 29, 2018